In inpatients with COVID-19 who need supplemental oxygen, lenzilumab increased ventilation-free survival

Vincent J Mariano; Eleftherios Mylonakis

doi:10.7326/J22-0019

In inpatients with COVID-19 who need supplemental oxygen, lenzilumab increased ventilation-free survival

Ann Intern Med. 2022 Apr;175(4):JC39. doi: 10.7326/J22-0019. Epub 2022 Apr 5.

Authors

Vincent J Mariano¹, Eleftherios Mylonakis¹

Affiliation

¹ Rhode Island Hospital/Brown University, Providence, Rhode Island, USA (V.J.M., E.M.).

PMID: 35377717
DOI: 10.7326/J22-0019

Abstract

Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:237-46. 34863332.

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
COVID-19*
Humans
Inpatients
Oxygen
SARS-CoV-2
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
lenzilumab
Oxygen